Oxidation-reduction drug and dye · Fact sheet

Methylene blue

Also known as Methylthioninium chloride · ProvayBlue

Methylene blue has an FDA-approved product for acquired methemoglobinemia, a blood oxygen-transport disorder. Small cognitive studies do not establish a general nootropic or anti-aging benefit, and serious drug interactions are a central concern.

FDA approved for specific usesEarly human evidence

What is Methylene blue?

Methylene blue is a redox-active small molecule and dye. Evidence for a regulated medical product cannot be transferred to technical dyes or unverified wellness preparations.

Benefits & claims

Mental clarity, memory, energy, and mitochondrial support drive interest. These claims concern different populations and outcomes from the approved blood-disorder indication.

What the evidence supports

  • ProvayBlue treats acquired methemoglobinemia in its labeled medical setting.
  • Small experiments found selected memory effects, but no dependable evidence of everyday cognitive enhancement or longer life.
Research areas
  • Acquired methemoglobinemia
  • Memory tasks
  • Fear-extinction learning

Dosage & frequency

Product-specific label information

Provayblue is an intravenous emergency medicine for acquired methemoglobinemia. Its weight-based label does not establish an oral nootropic regimen.

Provayblue

Adults and pediatric patients with acquired methemoglobinemia

Amount
1 mg/kg; one repeat dose after one hour may be considered under labeled criteria
Frequency
One monitored administration, with a possible second dose
Route studied or labeled
Intravenous

Emergency treatment over 5–30 minutes; renal impairment can limit repeat dosing.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Pharmaceutical methylene blue is distinct from nonmedical dye preparations.

Interactions & precautions

  • The boxed warning addresses serious serotonin syndrome with serotonergic medicines and opioids; G6PD deficiency is a contraindication.

What is still unresolved

  • A safe and effective repeated oral cognitive-enhancement regimen remains unestablished.

Side effects & risks

  • The label has a boxed warning about serious or fatal serotonin syndrome with serotonergic medicines and opioids.
  • G6PD deficiency is a contraindication because of hemolysis risk; severe allergy is also a concern.
  • Discoloration, headache, nausea, and altered taste are among reported effects. Pregnancy and lactation carry specific label precautions.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

The cognitive evidence includes a 26-person healthy-adult imaging study and a 42-person fear-learning study. Both are small and context-specific; this grade describes the frontier claims, not denial of the approved medical use.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Positive account · personal report

Calmer mood, clearer thinking and deeper sleep

A separate commenter described less fatigue, more enjoyment, calmer focus and deeper sleep over five days, alongside blue-green urine and an unpleasant taste.

Reported use in this account

Product
Product described as methylene blue
Amount
4 mg
Frequency
Not specified clearly
Route
Oral
Duration
Five days at the report

Other exposures described: Earlier psilocybin exposure

The short, unverified account and prior psilocybin exposure do not establish antidepressant efficacy or longer-term safety.

Read the original account

Approval status

ProvayBlue is FDA approved for acquired methemoglobinemia in pediatric and adult patients. Cognitive enhancement, anti-aging, and consumer oral preparations are not covered by that indication.

Approved uses

  • ProvayBlue: acquired methemoglobinemia in pediatric and adult patients

Approved for acquired methemoglobinemia

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Durable cognitive or functional benefit
  • Safety of repeated wellness exposure
  • Whether research preparations resemble products encountered online

Summary

Methylene blue is a medically active drug with a narrow approved use; its interactions matter more than confident online nootropic claims suggest.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. nihDailyMed: ProvayBlue prescribing information

    Current official label, approved indication, boxed warning, contraindications, and adverse reactions.

  2. pubmedMethylene blue, functional imaging, and memory

    26-person randomized experiment; short-term task and imaging outcomes.

  3. pubmedMethylene blue and fear-extinction learning

    42-person claustrophobia experiment; outcomes depended on successful versus unsuccessful exposure learning.

How we assess sources · Suggest a correction